Notably, PD-1 is an inhibitory receptor that has received considerable attention in the pharmaceutical sector, with PD1/PD-1 ligand (PD-L1) drugs effectively treating melanoma, renal carcinoma, and non-small cell lung cancer [71,75]. This evidence concerns the gene RPL17 and renal carcinoma.